Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

    -- Phase II SP 667 - 200, 400, 600 mg/day* Vimpat(R)
    -- Phase III SP 754 - 400, 600 mg/day* Vimpat(R)
    -- Phase III SP 755 - 200, 400 mg/day Vimpat(R)

* The 600 mg/day dose of Vimpat(R) is not approved by the FDA. In clinical trials, the 600 mg daily dose was not more effective than the 400 mg daily dose, and was associated with a substantially higher rate of adverse reactions. Vimpat(R) dosing should start at 50 mg twice daily and maybe increased to a daily dose of 200 to 400 mg per day (recommended therapeutic dosing) administered in two divided doses.

The primary endpoints of the studies were the median percent reduction in seizure frequency per 28 days from the baseline to the maintenance period and the 50 percent responder rate, defined as the proportion of patients experiencing a 50 percent or greater reduction in partial seizure frequency per 28 days from the baseline to the maintenance period.

The studies involved a total of more than 1,300 patients, with 944 randomized to receive Vimpat(R) at one of the three doses (200 mg/day, n=270; 400 mg/day, n=471; 600 mg/day, n=203) and 364 randomized to the placebo group. Patients in the treatment groups received Vimpat(R) at 100 mg/day (50 mg twice daily) during the initial week of treatment, followed by weekly titration in 100 mg/day increments to the assigned targeted dose.

This patient group had been living with epilepsy for an average of almost 24 years. Overall, 77.4 percent of patients had tried four or more AEDs in their lifetime and 45.2 percent had tried seven or more. Most patients (84.4 percent) were taking two or three concomitant AEDs at the time of study entry, mainly carbamazepine (35.2 percent), lamotrigine (31.2 percent), levetiracetam (29.0 percent), valproate (23.6 percent), and topiramate (22.3 percent). At baseline, patients reported more than two to three times the number of seizures per 2
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... & Brussels (PRWEB) December 22, 2014 ... (CfPIE), the global leader of technical training across the ... for Clinical Data Management (SCDM) to provide the ... certification programs —providing access to the more than ... extends SCDM members with 10% off when registering for ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5ALNE Announces Intention To Acquire BioTechPharma 2
... , , WASHINGTON , ... the National Institutes of Health and recipient of the nation,s highest ... February 26 Speaker Luncheon.  Topic of his talk will be ... was originally scheduled for December, but postponed because of snow. , ...
... For the first time the European research initiative EUREKA ... & Technology, which forms part of HANNOVER MESSE 2010 ... the Innovations Market for Research and Development in Hall ... that EUREKA makes as a central European platform with ...
... , EAST RUTHERFORD, N.J. , Feb. ... quarter results for the period ended December 31, 2009 . , ... and excluding the impact of foreign currency, sales decreased 15.8% compared to ... and decreased 1.2% excluding the impact of foreign currency. EBITDA was ...
Cached Biology Technology:NIH Director Francis Collins to Speak at National Press Club February 26 on 'A New Era of Quantum Leaps in Biomedical Research' 2NIH Director Francis Collins to Speak at National Press Club February 26 on 'A New Era of Quantum Leaps in Biomedical Research' 3European research initiative EUREKA presented at Research & Technology for the first time 2Cambrex Reports Fourth Quarter and Full Year 2009 Results 2Cambrex Reports Fourth Quarter and Full Year 2009 Results 3Cambrex Reports Fourth Quarter and Full Year 2009 Results 4Cambrex Reports Fourth Quarter and Full Year 2009 Results 5Cambrex Reports Fourth Quarter and Full Year 2009 Results 6Cambrex Reports Fourth Quarter and Full Year 2009 Results 7Cambrex Reports Fourth Quarter and Full Year 2009 Results 8Cambrex Reports Fourth Quarter and Full Year 2009 Results 9Cambrex Reports Fourth Quarter and Full Year 2009 Results 10Cambrex Reports Fourth Quarter and Full Year 2009 Results 11Cambrex Reports Fourth Quarter and Full Year 2009 Results 12Cambrex Reports Fourth Quarter and Full Year 2009 Results 13Cambrex Reports Fourth Quarter and Full Year 2009 Results 14Cambrex Reports Fourth Quarter and Full Year 2009 Results 15
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... the iPhone 5S, Samsung introduces for the first ... The Galaxy S5 home button presents an ...
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... as essential health benefits, habilitative services face an uncertain ... new analysis done at the George Washington University School ... parents of children with developmental disabilities have trouble getting ... children keep, learn or improve their skills and daily ...
... dairy products is vital to maintaining good overall health, ... has been little research about how dairy products affect ... study published in the May/June 2013 issue of ... Academy of General Dentistry (AGD), consuming cheese and other ...
... This news release is available in German . ... bees are dying and insect diversity is dwindling. Only recently, both ... decline, which jeopardises food security. The (lack of) pollination has thus ... habitats, and organic farming. ETH-Zurich researchers from the group headed ...
Cached Biology News:Habilitative services under health reform faces uncertainty, new analysis says 2New research shows cheese may prevent cavities 2Pollination merely 1 production factor 2Pollination merely 1 production factor 3Pollination merely 1 production factor 4
ABI Plant AFLP Kits • EcoRI-ACA AFLP Amplification Primers...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Penicillin-Streptomycin liquid...
...
Biology Products: